keyboard_arrow_down
Genetic screening, as part of fertility treatment, can improve the chance of success, potentially reduce time in care, and provide patients and their care team with powerful information for supporting a healthy pregnancy and delivery.
RMA uses NexCCS, the most advanced embryo screening platform available for IVF today. Validated over several years and multiple rigorous clinical trials, NexCCS can accurately determine if an embryo possesses the right number of chromosomes (euploidy) or too few or too many (aneuploidy). This is important because published data suggests 50-70% of miscarriages are due to aneuploidy. Selection with NexCCS can substantially reduce these risks.
Greater than 98% accuracy1
Ability to detect more subtle abnormalities in embryos, such as mosaicism and segmental abnormalities2
69% delivery rate in a large-scale clinical trial3
Greatly increases the effectiveness of Single Embryo Transfer (SET) for a healthier pregnancy
In the U.S., approximately half of all babies conceived following IVF were born as part of a twin or triplet pregnancy. These pregnancies typically result from a multiple embryo transfer and are associated with a significantly increased risk of problems for the mother and baby.
Utilizing NexCCS to choose the single best embryo for transfer makes the promise of Single Embryo Transfer (SET) a reality and provides a safer and more effective treatment option for many patients.4
To begin aneuploidy screening with NexCCS, a sample is biopsied (safely removed) from an embryo. The method of biopsy used in NexCCS has been determined to be the safest available. Approximately five cells are removed from a specific area of the embryo called the trophectoderm at a specific time in embryonic development.
Unlike other methods of biopsy, a trophectoderm biopsy has no significant impact on the reproductive potential of the embryo and therefore maximizes the benefit of NexCCS. The biopsied cells are then sent to the FEC where they are analyzed. About seven days later, a report is sent to the patient’s IVF team.
Once the NexCCS report comes in, the doctor will notify the patient to review the results.
